Long-term oral treatment with tafamidis meglumine safely helped maintain nerve function, quality of life, nutritional status, and mobility in…
Articles by Margarida Maia, PhD
A protein called glial fibrillary acidic protein (GFAP) is found at higher levels in the blood of people with…
Family members of people with late-onset familial amyloid polyneuropathy (FAP) may face emotional and practical challenges due to the…
Tafamidis meglumine safely and effectively slows disease progression in most people living with familial amyloid polyneuropathy (FAP), according…
The first adult with familial amyloid polyneuropathy (FAP) has been dosed in a Phase 3 clinical trial testing nexiguran…
The U.S. Food and Drug Administration (FDA) has granted orphan drug status to ART001, a gene editing candidate that…
The U.S. Food and Drug Administration (FDA) has extended the approval of Amvuttra (vutrisiran) to adults with cardiomyopathy (heart…
Wainzua (eplontersen) is now approved in the European Union (EU) for treating adults with early-stage familial amyloid polyneuropathy (FAP). With…
Alnylam Pharmaceuticals is planning to launch a Phase 3 clinical trial toward the end of this year to test…
Throughout March — Amyloidosis Awareness Month — the Amyloidosis Foundation is inviting the public to join its “Light the…